Lukas C Heukamp
Overview
Explore the profile of Lukas C Heukamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
4633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sprussel A, Suzuki T, Miyata N, Astrahantseff K, Szymansky A, Toedling J, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458030
The KDM1A histone demethylase regulates the cellular balance between proliferation and differentiation, and is often deregulated in human cancers including the childhood tumor neuroblastoma. We previously showed that KDM1A is...
2.
Jori B, Bundschuh O, Falk M, Heukamp L, Kluge A, Tiemann M, et al.
Transl Lung Cancer Res
. 2024 Aug;
13(7):1749-1755.
PMID: 39118880
Background: Capmatinib, a potent and selective tyrosine kinase inhibitor (TKI), holds promise as a therapeutic agent due to its potentially elevated intracranial efficacy in metastatic non-small cell lung cancer (NSCLC)...
3.
Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300348.
PMID: 38513168
Purpose: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency...
4.
Lohanadan K, Assent M, Linnemann A, Schuld J, Heukamp L, Krause K, et al.
Cells
. 2024 Jan;
13(1).
PMID: 38201288
Synaptopodin-2 (SYNPO2) is a protein associated with the Z-disc in striated muscle cells. It interacts with α-actinin and filamin C, playing a role in Z-disc maintenance under stress by chaperone-assisted...
5.
Jori B, Vossing C, Pirngruber J, Willing E, Arndt K, Falk M, et al.
Curr Oncol
. 2023 Oct;
30(10):8805-8814.
PMID: 37887535
EGFR-mutant lung cancers develop a wide range of potential resistance alterations under therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET amplification ranks among the most common acquired resistance...
6.
Willing E, Vollbrecht C, Vossing C, Weist P, Schallenberg S, Herbst J, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444554
The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine...
7.
Mohrmann L, Cuberi A, Bruckmann S, Stasik S, Heukamp L, Bornhauser M, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200666.
PMID: 37262393
No abstract available.
8.
Jori B, Falk M, Hovel I, Weist P, Tiemann M, Heukamp L, et al.
Curr Oncol
. 2022 Sep;
29(9):6628-6634.
PMID: 36135089
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment...
9.
Roeper J, Christopoulos P, Falk M, Heukamp L, Tiemann M, Stenzinger A, et al.
Transl Lung Cancer Res
. 2022 Mar;
11(1):4-13.
PMID: 35242623
Background: The negative prognostic and predictive value of co-mutations ( mt+) in mutated ( mt+) non-small cell lung cancer (NSCLC) is increasingly being acknowledged. Data consistently show that mt+ impact...
10.
Heitz F, Lakis S, Harter P, Heikaus S, Sehouli J, Talwar J, et al.
PLoS One
. 2022 Feb;
17(2):e0262770.
PMID: 35130283
Background: The present prospective study aimed at determining the impact of cell-free tumor DNA (ct-DNA), CA125 and HE4 from blood and ascites for quantification of tumor burden in patients with...